| A Study of Blood-stage Controlled Human Plasmodium Falciparum Malaria Infection in Tanzania (NCT04788862) | University of Oxford | 2022-07-18 |
| The Malaria Heart Disease Study (NCT04445103) | University Hospital, Gentofte, Copenhagen | 2020-06-21 |
| A Clinical Trial to Evaluate Plasmodium Falciparum 7G8 and NF54 Challenge Strains (PfSPZ) in a Head-to-head Comparative Study - (ECG-CHMI) (NCT04203186) | U.S. Army Medical Research and Development Command | 2020-03-01 |
| Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children (NCT03452475) | University of Oxford | 2018-03-07 |
| Clinical Performance of the HRP2 HS-RDT for Malaria Diagnosis in Pregnant Women (NCT03172221) | Foundation for Innovative New Diagnostics, Switzerland | 2017-07-25 |
| ELISA Validation of Hypersensitive Rapid Diagnostic Test Results for Detection of P. Falciparum (NCT03132402) | University of Oxford | 2017-06-01 |
| Safety and Protective Efficacy of Pb(PfCS@UIS4) (NCT03138096) | Radboud University Medical Center | 2017-05-29 |
| Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance Markers (NCT02895568) | University of Oxford | 2016-09-16 |
| Safety and Protective Efficacy of BCG Vaccination Against Controlled Human Malaria Infection (NCT02692963) | Radboud University Medical Center | 2016-04-01 |
| Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated PfSPZ Vaccine in Equatoguinean Adults (NCT02418962) | Sanaria Inc. | 2015-03-01 |
| Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission (NCT02259426) | London School of Hygiene and Tropical Medicine | 2014-10-01 |
| A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5 (NCT02181088) | University of Oxford | 2014-08-01 |
| Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes (NCT02090036) | Muhimbili University of Health and Allied Sciences | 2014-07-01 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO (NCT01930331) | Ifakara Health Institute | 2014-01-07 |
| Low Dose Primaquine for Clearance of Gametocytes (NCT01935882) | London School of Hygiene and Tropical Medicine | 2013-09-01 |
| Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis (NCT01728701) | Sanaria Inc. | 2012-09-01 |
| Plasmodium Falciparum Artemisinin Resistance Vietnam (NCT01775592) | National Institute of Malariology, Parasitology and Entomology, Vietnam | 2012-09-01 |
| Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis (NCT01422954) | Radboud University Medical Center | 2012-01-01 |
| Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe (NCT01465048) | University of Oxford | 2011-10-01 |
| Pilot Study to Estimate the Burden and Distribution of Plasmodium Falciparum Malaria in Kalifabougou, Mali in Preparation for a Prospective Cohort Study of Naturally-Acquired Malaria Immunity (NCT01160562) | National Institute of Allergy and Infectious Diseases (NIAID) | 2010-06-23 |
| Comparison of Three Plasmodium Falciparum Isolates in an Experimental Human Malaria Infection (NCT01002833) | Radboud University Medical Center | 2010-04-01 |
| Clinical Trial of the PfSPZ Vaccine (NCT01001650) | Sanaria Inc. | 2009-04-01 |
| NMRC-M3V-Ad-PfCA Vaccine - Clinical Trial 1 (NCT00392015) | U.S. Army Medical Research and Development Command | 2006-10-12 |
| Antimalarial Treatments for Clearing Low Density P. Falciparum and Its Impact on Malaria Transmission (NCT00646126) | Tropical Medicine Research Institute | 2005-08-01 |
| Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults. (NCT00197054) | U.S. Army Medical Research and Development Command | 2005-07-01 |
| PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria (NCT00295581) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-03-07 |